AcuityBio has entered into agreements with Cook Biotech. Under the terms of the agreements, both companies will collaborate in the advancement of AcuityBio’s ABC103 lead product for lung cancer, which will utilize Cook Biotech’s proprietary extracellular matrix (ECM) technology.
“We are excited about the possibilities that this new collaboration brings,” said AcuityBio President and CEO John “Jay” Schwartz, PhD. “We believe that the solidification of our relationship with Cook Biotech will allow us to build on our two companies’ strengths, such as AcuityBio’s drug-delivery expertise and Cook Biotech’s unique medical device technology platform, know how, and market experience. Working together will speed development of our combined AcuityBio-Cook Biotech lead product for lung cancer, ABC103, ultimately providing a solution to a critical unmet medical need and the betterment of patient outcomes.”
“For more than 20 years, our ECM technology has been used to improve the lives of patients worldwide. We are excited to partner with AcuityBio to help bring a medical solution that can potentially save lives,” Cook Biotech President Umesh Patel, PhD, said.
The terms of the agreements remain confidential.